OMNIPAQUE 180 Drug Patent Profile
✉ Email this page to a colleague
When do Omnipaque 180 patents expire, and when can generic versions of Omnipaque 180 launch?
Omnipaque 180 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in OMNIPAQUE 180 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNIPAQUE 180?
- What are the global sales for OMNIPAQUE 180?
- What is Average Wholesale Price for OMNIPAQUE 180?
Summary for OMNIPAQUE 180
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 25 |
Patent Applications: | 3,615 |
DailyMed Link: | OMNIPAQUE 180 at DailyMed |
Recent Clinical Trials for OMNIPAQUE 180
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fédération des médecins résidents du Québec | Phase 4 |
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | Phase 4 |
Claire Bourgeois | Phase 4 |
Pharmacology for OMNIPAQUE 180
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OMNIPAQUE 180
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | OMNIPAQUE 180 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-001 | Dec 26, 1985 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNIPAQUE 180
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | OMNIPAQUE 180 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-001 | Dec 26, 1985 | 4,021,481 | ⤷ Subscribe |
Ge Healthcare | OMNIPAQUE 180 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-001 | Dec 26, 1985 | 4,396,597 | ⤷ Subscribe |
Ge Healthcare | OMNIPAQUE 180 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-001 | Dec 26, 1985 | 4,250,113 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNIPAQUE 180
See the table below for patents covering OMNIPAQUE 180 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Sweden | 445971 | FORFARANDE FOR FRAMSTELLNING AV INJICERBART RONTGENKONTRASTMEDEL SAMT EN LOSNING AV NEMNDA MEDEL | ⤷ Subscribe |
Ireland | 48437 | A PROCESS FOR THE PREPARATION OF A STERILE INJECTABLE PHYSIOLOGICALLY ACCEPTABLE SOLUTION OF AN X-RAY CONTRAST AGENT AND SOLUTIONS OF THE X-RAY CONTRAST AGENT AND A BUFFER | ⤷ Subscribe |
Finland | 792101 | ⤷ Subscribe | |
France | 2053037 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |